Pharmacological investigations on lonidamine.
The results of a broad pharmacological screening on 1-[(2,4-dichlorophenyl)-methyl] -1H-indazole-3-carboxylic acid ( lonidamine ) a new antitumour agent which also possesses antispermatogenic and embryotoxic effects, are reported. Lonidamine does not affect general behaviour and autonomic functions and is devoid of anticonvulsant, anti-reserpine, anti-apomorphine, anti-amphetamine, antitremor , antipyretic, antiinflammatory and analgesic effects. It also lacks those side effects which are considered characteristic of different antitumour agents, such as thymus and spleen atrophy, delay in skin wound healing and damage to the gastrointestinal mucosa. At doses 40 times higher than that of hydrochlorothiazide, lonidamine produces diuretic effects. The practical importance of these findings in the current therapeutic use of lonidamine appears to be limited. The most typical signs of acute intoxication produced by high doses of lonidamine are salivation, lacrimation, diarrhea, ataxia, muscle rigidity and prostration with superimposed convulsions.
D000818:Animals; D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D001679:Biogenic Amines / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D002490:Central Nervous System / Q000378:metabolism; D002756:Cholagogues and Choleretics; D004064:Digestive System / Q000187:drug effects; D004232:Diuretics; D005260:Female; D006168:Guinea Pigs; D007191:Indazoles / Q000494:pharmacology* / Q000633:toxicity; D008297:Male; D051379:Mice; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D013154:Spleen / Q000187:drug effects; D013950:Thymus Gland / Q000187:drug effects
D000890:Anti-Infective Agents; D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D001679:Biogenic Amines; D002756:Cholagogues and Choleretics; D004232:Diuretics; D007191:Indazoles; D011720:Pyrazoles; C016371:lonidamine